Biology of cord blood cells and future prospects for enchanced clinical benefit

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Cord blood (CB) has served as a clinically beneficial source of hematopoietic stem (HSC) and progenitor (HPC) cells for transplantation and correction of a large number of malignant and non-malignant disorders. The capacity of CB to perform these functions is intimately related to the quality and quantity of HSC and HPC present in CB. This review covers the biology of HSC and HPC, efforts to expand these cells ex vivo for enhanced clinical utility that has thus far not been very successful, and recent studies on attempts to enhance the homing and engrafting capability of HSC as an alternative means for more effective use of the limited numbers of CB cells collected. This review also highlights the presence in CB of mesenchymal stem cells, unrestricted somatic stem cells, endothelial progenitor cells and immune cells. The presence and biology of these non-HSC/HPC may open up future possibilities for additional clinical benefit of CB, a product considered mainly for discard before its clinical transplantation potential was realized in the late 1980s.

Original languageEnglish
Pages (from-to)209-218
Number of pages10
JournalCytotherapy
Volume7
Issue number3
DOIs
StatePublished - 2005

Fingerprint

Fetal Blood
Blood Cells
Adult Stem Cells
Blood Cell Count
Cell Transplantation
Mesenchymal Stromal Cells
Stem Cells
Transplantation

Keywords

  • Cord Blood
  • Endothelial progenitor cells
  • Hematopoietic stem and progenitor cells
  • Immune cells
  • Mesenchymal stem cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Biology of cord blood cells and future prospects for enchanced clinical benefit. / Broxmeyer, Hal.

In: Cytotherapy, Vol. 7, No. 3, 2005, p. 209-218.

Research output: Contribution to journalArticle

@article{32886bb4a2b749c6bced0325089e9220,
title = "Biology of cord blood cells and future prospects for enchanced clinical benefit",
abstract = "Cord blood (CB) has served as a clinically beneficial source of hematopoietic stem (HSC) and progenitor (HPC) cells for transplantation and correction of a large number of malignant and non-malignant disorders. The capacity of CB to perform these functions is intimately related to the quality and quantity of HSC and HPC present in CB. This review covers the biology of HSC and HPC, efforts to expand these cells ex vivo for enhanced clinical utility that has thus far not been very successful, and recent studies on attempts to enhance the homing and engrafting capability of HSC as an alternative means for more effective use of the limited numbers of CB cells collected. This review also highlights the presence in CB of mesenchymal stem cells, unrestricted somatic stem cells, endothelial progenitor cells and immune cells. The presence and biology of these non-HSC/HPC may open up future possibilities for additional clinical benefit of CB, a product considered mainly for discard before its clinical transplantation potential was realized in the late 1980s.",
keywords = "Cord Blood, Endothelial progenitor cells, Hematopoietic stem and progenitor cells, Immune cells, Mesenchymal stem cells",
author = "Hal Broxmeyer",
year = "2005",
doi = "10.1080/14653240510027190",
language = "English",
volume = "7",
pages = "209--218",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Biology of cord blood cells and future prospects for enchanced clinical benefit

AU - Broxmeyer, Hal

PY - 2005

Y1 - 2005

N2 - Cord blood (CB) has served as a clinically beneficial source of hematopoietic stem (HSC) and progenitor (HPC) cells for transplantation and correction of a large number of malignant and non-malignant disorders. The capacity of CB to perform these functions is intimately related to the quality and quantity of HSC and HPC present in CB. This review covers the biology of HSC and HPC, efforts to expand these cells ex vivo for enhanced clinical utility that has thus far not been very successful, and recent studies on attempts to enhance the homing and engrafting capability of HSC as an alternative means for more effective use of the limited numbers of CB cells collected. This review also highlights the presence in CB of mesenchymal stem cells, unrestricted somatic stem cells, endothelial progenitor cells and immune cells. The presence and biology of these non-HSC/HPC may open up future possibilities for additional clinical benefit of CB, a product considered mainly for discard before its clinical transplantation potential was realized in the late 1980s.

AB - Cord blood (CB) has served as a clinically beneficial source of hematopoietic stem (HSC) and progenitor (HPC) cells for transplantation and correction of a large number of malignant and non-malignant disorders. The capacity of CB to perform these functions is intimately related to the quality and quantity of HSC and HPC present in CB. This review covers the biology of HSC and HPC, efforts to expand these cells ex vivo for enhanced clinical utility that has thus far not been very successful, and recent studies on attempts to enhance the homing and engrafting capability of HSC as an alternative means for more effective use of the limited numbers of CB cells collected. This review also highlights the presence in CB of mesenchymal stem cells, unrestricted somatic stem cells, endothelial progenitor cells and immune cells. The presence and biology of these non-HSC/HPC may open up future possibilities for additional clinical benefit of CB, a product considered mainly for discard before its clinical transplantation potential was realized in the late 1980s.

KW - Cord Blood

KW - Endothelial progenitor cells

KW - Hematopoietic stem and progenitor cells

KW - Immune cells

KW - Mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=22944453703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944453703&partnerID=8YFLogxK

U2 - 10.1080/14653240510027190

DO - 10.1080/14653240510027190

M3 - Article

VL - 7

SP - 209

EP - 218

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 3

ER -